About this episode

Dr Andree Bates discusses the implications of the EU AI Act's deadline extension and the ongoing governance exposure for companies.

On 7 May 2026, the EU reached a provisional agreement to push back the hardest deadlines in the EU AI Act. Many leadership teams heard one message: “we’ve got more time”. In this solo episode, Dr Andree Bates explains why that exhale is dangerous. The timeline moved, but the governance exposure did not. Dr Andree breaks down what the delay does and does not change. The dates may shift, but the architecture of the AI Act remains intact: risk classification, documentation, oversight, robustness, logging, conformity assessment, and post market monitoring. These are not last minute checklist items. They are operational capabilities you have to build, test, and keep running. The real risk, she argues, is misreading “more time” as permission to wait. The hardest work is operational: finding every AI system across the enterprise, including vendor embedded AI inside platforms like CRM and workflow tools, distinguishing genuine AI from marketing labels, classifying systems properly, assigning ownership, and building processes that still hold when vendors update models or features under the hood. She also tackles a costly misconception for US based pharma: the EU AI Act is deliberately…

People in this episode

Host: Dr Andree Bates

Topics covered

• AI governance
• EU AI Act
• operational capabilities
• risk classification
• pharma industry
• extraterritorial regulations

Keywords

• AI governance
• EU AI Act
• risk classification
• operational capabilities
• pharma regulations
• extraterritorial scope
• AI systems

Mentioned in this episode

Organizations: EU, US

Explore listener stats, chart rankings, contacts and more on the AI For Pharma Growth podcast page.